Development and evaluation of low-volume tests to detect and characterise antibodies to SARS-CoV-2
Authors:
- Alice HallidayAHAlice Halliday
- Anna E LongALAnna E Long
- Holly E BaumHBHolly E Baum
- Amy C ThomasATAmy C Thomas
- Kathryn L ShelleyKSKathryn L Shelley
- Elizabeth OliverEOElizabeth Oliver
- Kapil GuptaKGKapil Gupta
- Ore FrancisOFOre Francis
- Maia Kavanagh WilliamsonMWMaia Kavanagh Williamson
- Natalie di BartoloNBNatalie di Bartolo
- Matthew J RandellMRMatthew J Randell
- Yassin Ben-KhoudYBYassin Ben-Khoud
Preprint
Abstract
Low-volume antibody assays can be used to track SARS-CoV-2 infection rates in settings where active testing for virus is limited and remote sampling is optimal. We developed 12 ELISAs detecting total or antibody isotypes to SARS-CoV-2 nucleocapsid, spike protein or its receptor binding domain (RBD), 3 anti-RBD isotype specific luciferase immunoprecipitation system (LIPS) assays and a novel Spike-RBD bridging LIPS total-antibody assay. We utilised pre-pandemic (n=984) and confirmed/suspected recent COVID-19 sera taken pre-vaccination rollout in 2020 (n=269). Assays measuring total antibody discriminated best between pre-pandemic and COVID-19 sera and were selected for diagnostic evaluation. In the blind evaluation, two of these assays (Spike Pan ELISA and Spike-RBD Bridging LIPS assay) demonstrated >97% specificity and >92% sensitivity for samples from COVID- 19 patients taken >21 days post symptom onset or PCR test. These assays offered better sensitivity for the detection of COVID-19 cases than a commercial assay which requires 100-fold larger serum volumes. This study demonstrates that low-volume in- house antibody assays can provide good diagnostic performance, and highlights the importance of using well-characterised samples and controls for all stages of assay development and evaluation. These cost-effective assays may be particularly useful for seroprevalence studies in low and middle-income countries.Keywords
This publication has 34 references indexed in Scilit:
- Antibody tests for identification of current and past infection with SARS-CoV-2Cochrane Database of Systematic Reviews, 2020
- LIPS method for the detection of SARS‐CoV‐2 antibodies to spike and nucleocapsid proteinsEuropean Journal of Immunology, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- The Effect of Pre-Analytical Conditions on Blood Metabolomics in Epidemiological StudiesMetabolites, 2019
- A novel LIPS assay for insulin autoantibodiesActa Diabetologica, 2018
- STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaborationBMJ Open, 2016
- Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohortInternational Journal of Epidemiology, 2012
- Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJournal of Virological Methods, 2010
- Baculovirus expression system for heterologous multiprotein complexesNature Biotechnology, 2004
- The determination of detection limits for insulin antibody assaysDiabetologia, 1988